The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis

BACKGROUND: Age is closely related to the efficacy of treatment for non-small cell lung cancer (NSCLC) patients. Latest clinical trials have proved the better overall survival (OS) for the use of immune checkpoint inhibitors verse chemotherapy in NSCLC patients. However, we had no clear idea of the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Transl Oncol
Päätekijät: Zheng, S.-Y., Cui, H.-J., Duan, H., Peng, Y.-M., Li, Q., Sun, C.-Y., Zhang, J.-Y., Shen, W., Zhang, X., Tan, K., Jiang, X.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260274/
https://ncbi.nlm.nih.gov/pubmed/31748961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12094-019-02241-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia